Long non-coding RNA ZNFX1-AS1 promotes the tumor progression and metastasis of colorectal cancer by acting as a competing endogenous RNA of miR-144 to regulate EZH2 expression

Liangliang Shi1, Xiaohua Hong1, Li Ba1, Xiaoxiao He1, Yin Xiong1, Qian Ding1, Shengli Yang1 and Gang Peng1

Abstract
Mounting evidences indicated that long non-coding RNA is dysregulated and involved in the pathology of tumors. However, the role of lncRNAs in colorectal cancer (CRC) progression is not fully determined. Differentially expressed lncRNA profile in CRC was conducted by lncRNA microarray in 15 pairs of CRC tissues and adjacent normal tissues, and validated by real-time PCR analysis in another 106 pairs of tissues. The biological effect of IncRNA ZNFX1-AS1 was evaluated by in vitro and in vivo assays. The regulation between IncRNA ZNFX1-AS1 and miR-144 was evaluated by a series of experiments. We found that IncRNA ZNFX1-AS1 expression was significantly upregulated in CRC tissues and cell lines, and the expression of IncRNA ZNFX1-AS1 was associated with aggressive tumor phenotype and poor prognosis in CRC. Functionally, knockdown of IncRNA ZNFX1-AS1 inhibited cell proliferation, invasion, in vitro and tumorigenesis and metastasis in vivo. Further investigation demonstrated that IncRNA ZNFX1-AS1 functioned as a competing endogenous RNA (ceRNA) for miR-144, thereby leading to the depression of its endogenous target gene Polycomb group protein enhancer of zeste homolog 2 (EZH2). We found that IncRNA ZNFX1-AS1 is significantly upregulated in CRC, and the newly identified IncRNA ZNFX1-AS1-miR-144-EZH2 axis is involved in the regulation of CRC progression, which might be used as potential therapeutic targets for CRC patients.

Introduction
In recent years, integrative genomic and transcriptome sequencing have indicated that more than 90% of the DNA sequence is actively transcribed, with 98% of these genomes transcribed into non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long ncRNAs (lncRNAs). Among these ncRNAs, miRNAs have been found to be aberrantly expressed in both mammalian cells and plant cells, these lncRNAs are implicated in multiple biological processes through acting as guides, scaffolds, decoys, and tethers of other biological molecules. Increasing studies have demonstrated that lncRNAs can be used as diagnostic and prognostic biomarkers in different tumors, including gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer.

Colorectal cancer (CRC) is the second most common and the third leading cause of cancer-related deaths...
worldwide. In spite of recent development in the treatment of CRC, the prognosis is still unsatisfactory, especially in advanced stage patients. Tumor progression and distant metastasis are the main causes of deaths in CRC patients, and the processes of which are complicated that involve a series of complex genetic and epigenetic changes. Therefore, it is compelling needed to seek out the molecular that drive CRC metastasis and progression and illuminate its underlying mechanisms.

In this study, we performed microarray analysis using 15 paired CRC tissues and adjacent normal tissues for CRC-related IncRNA screening, and the screening results were validated in a larger cohort of 106 paired CRC tissues. A significantly upregulated IncRNA, IncRNA ZNFX1-AS1 was identified, which could promote cell proliferation, invasion, tumorigenesis, and metastasis of CRC cells. Further study indicated that IncRNA ZNFX1-AS1 exerted its effects by acting as a competing endogenous RNA (ceRNA) for miR-144 to regulate the expression of Polycomb group protein enhancer of zeste homolog 2 (EZH2). Collectively, these results indicated that IncRNA ZNFX1-AS1 is significantly upregulated in CRC, and the newly identified IncRNA ZNFX1-AS1-miR-144-EZH2 axis is involved in the regulation of CRC progression, which might be used as potential therapeutic targets for CRC patients.

Methods

Patients and tissue samples
A total of 15 patients with primary CRC tissues and adjacent normal tissues who undergone radical resection in Union Hospital, Tongji medical college, Huazhong University of Science and Technology from May 2012 to March 2013 were enrolled in this study for microarray analysis, and another 106 patients with primary CRC tissues and adjacent normal tissues who undergone radical resection in Union hospital, Tongji Medical college, Huazhong University of Science and Technology from January 2011 to April 2013 were used in this study as the validation. None of the patients receive any chemotherapy or radiotherapy before resection. The tissues were collected during surgery and immediately snap-frozen in liquid nitrogen and stored at −80°C or paraffin-embedded. The patients were followed-up regularly and the clinical characteristics of the patients were recorded. This study has been approved by the institutional ethics review board of Union Hospital, Tongji Medical College, Huazhong University of Science And Technology and informed consent was obtained.

RNA extraction and microarray analysis
Total RNA from tissues (15 CRC tissues and paired adjacent normal tissues) was extracted with Trizol reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s instructions. The RNA was quantified by NanoDrop ND-1000 and qualified by formaldehyde agarose gel electrophoresis. The microarray experiment was conducted by Kangcheng Bio-tech Inc (Shanghai, China).

Real-time PCR analysis
RNA was isolated from tissues and cells with Trizol reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s instructions. The PCR analysis for IncRNAs, miRNAs, and mRNAs was performed as we previously described. β-actin, GAPDH, and snRNA U6 were used as internal positive control.

RNA isolation and nuclear and cytoplasmic fractions
The nuclear and cytoplasm fraction of cells were separated with PARA Kit (Life Technology) according to the manufacturer’s guidelines. Real-time PCR was carried out to detect the expression ratios of specific RNA molecules between the nuclear and cytoplasm fractions. GAPDH and snRNA U6 served as the cytoplasm and the nuclear marker, respectively.

Cell culture
Human CRC cell lines (SW620, SW480, HT-29, DLD-1, RKO, LOVO), human normal colon epithelial cell line CCD-112CoN, and human embryonic kidney (HEK) 293T cell were purchased from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China) or the American Type Culture Collection (Manassas, VA, USA) and cultured and stored according to the provider’s instructions. All the cell lines were routinely authenticated by short tandem repeat DNA profiling.

siRNAs and miRNA transfection and plasmid construction
CRC cells were transfected with siRNAs using Lipotamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. The IncRNA ZNFX1-AS1 siRNAs (si-ZNFX1-AS1 #1 and #2), EZH2 siRNA (si-EZH2), and scramble negative control siRNA (si-NC) were obtained from GenePhama (Shanghai, China). miR-144 mimics, miR-144 inhibitor and negative controls were purchased from RiboBio (Guangzhou, China). Human IncRNA ZNFX1-AS1 transcript cDNA was constructed into pcDNA3.1 vector.

Lentivirus production and transduction
Short hairpin RNA (shRNA) targeted human IncRNA ZNFX1-AS1 or scrambled oligonucleotides were constructed into the LV-3 (pGLVH1/GFP + Puro) vector (GenePharma, Shanghai, China). HEK293T cells were cotransfected with Lenti-Pac HIV Expression Packaging Mix and the lentiviral vectors (or the control lentivirus vectors) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), lentiviral particles in the supernatant were harvested at 48 h and 72 h after transfection. Cells were then
transfected with lentivirus or control virus (NC). The cells were treated with puromycin (2 μg/mL) for two weeks to select the stably transfected cells, GFP-positive cells were picked as sh-ZNFX1-AS1 and sh-NC and then used for subsequent assays.

**Cell viability and cell proliferation assay**

The Cell Counting Kit 8 (CCK-8) was used to detect cell viability according to the manufacturer’s instructions. Briefly, cells were cultured in a 96-well plate, and the plates were incubated at 37 °C for 2 h after CCK-8 solution was added, then, the spectrophotometric absorbance at 450 nm for each sample was measured. Cell proliferation was assessed by colony formation assay. Cells were trypsinized, and approximately 2000 cells were seeded in each well of the 6-well plates and cultured for 2 weeks under a humidified atmosphere. Cell colonies were then fixed with methanol, stained with 0.1% crystal violet (1 mg/mL). Colonies containing more than 50 cells were counted and the mean colony numbers were calculated. All the experiments were conducted in triplicate and repeated for 3 times.

**Cell wounding, migration, and invasion assay**

Wound healing assay and transwell assays were used to measure cell migration and invasion ability. The details were described in our previously study.

**Tumorigenesis and metastasis assays**

The Female BABL/c athymic nude mice (4–5 week-old) were purchased from the Beijing Vital River Laboratory Animal Technology Co., Ltd (Beijing, China) and kept under pathogen-free conditions. For tumorigenesis assay, cells were injected into the right flanks of nude mice. The weights and volumes of tumors were examined every 5 days. The mice were killed 30 days post-injection, and the tumors were exercised and weighted. For metastasis assay, cells were inoculated into the tail vein of nude mice, 30 days later, the mice were killed and the lungs and livers of the mice were collected and paraffin embedded, consecutive sections (4 μm) were made and stained with hematoxylin-eosin. The micro-metastases in the lungs and livers were evaluated under a dissecting microscope.

**Vector construction and luciferase reporter assay**

The fragment containing the wild type (wt) and mutant type (mt) of IncRNA ZNFX1-AS1 fragment and 3’-untranslated region (UTR) of EZH2 was amplified and subcloned into a pmirGLO luciferase Target Expression Vector (Promega, Madison, WI, USA). The HEK293T cells were co-transfected with either empty vectors or miR-144, miR-135a-5p, miR-150, miR-15, miR-199, miR-101, and miR-10a, firefly luciferase reporter containing wild type or mutant type of IncRNA ZNFX1-AS1 and 3’-UTR of EZH2 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The luciferase activity was measured using the Dual-Luciferase Reporter Assay Kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions.

**RNA immunoprecipitation (RIP) assay**

RIP assay was performed by using a Magna RNA-binding protein immunoprecipitation kit (Millipore, Bedford, MA) according to a previously described method.

**Western blotting and immunofluorescence analysis**

The process of western blotting and immunofluorescence analysis was performed following a previously method. The antibody for EZH2 (CST, #5246), E-cadherin (#3199S), N-cadherin (#14215S) was purchased from Cell Signaling Technology, and the antibody for GAPDH (Abcam, #AB127428) was used as the loading control.

**Immunohistochemistry (IHC) analysis**

The paraffin-embedded tissue blocks were cut into 4 μm slides. The antibody for EZH2 (CST, #5246) was used. IHC analysis was performed according to a previously described method.

**Statistical analysis**

For continuous variables, the results were expressed as mean ± SD. Student’s t-test (unpaired, two-tailed) or one-way ANOVA was applied to compare the means between two or multiple groups. Kaplan–Meier method with log-rank test was performed to evaluate the overall survival. The correlations between IncRNA ZNFX1-AS1 and miR-144 as well as EZH2 were analyzed by using Spearman’s rank test. All the statistic analyses were performed using the GraphPad Prism 5.0 (GraphPad Software, Inc, CA, USA) or the SPSS (version 16.0, SPSS Inc., Chicago, IL, USA). A p-value of <0.05 was considered to be statistically significant.

**Results**

**IncRNA ZNFX1-AS1 is significantly upregulated in CRC**

IncRNA microarray was performed in 15 pairs of CRC tissues and adjacent normal tissues to identify the IncRNA expression profile in CRC. A total of 101 IncRNAs was identified to be differentially expressed between the two groups, including upregulated (n = 36) and downregulated (n = 65) IncRNAs (Supplementary Figure S1A). To confirm the microarray results, we randomly selected the top 10 IncRNAs that were upregulated in CRC for validation using real-time PCR analysis, the results showed that 6 of these IncRNAs were upregulated in CRC tissues compared with adjacent normal tissues
(Supplementary Figure S2). To further select the lncRNA that plays critical role in the progression of CRC, the expression of the above 6 lncRNAs was measured in another 106 paired CRC tissues and normal tissues using real-time PCR. The results showed that only lncRNA ZNFX1-AS1 (Accession: NR_003604, a 1008 bp transcript, locates in chromosome 20q13.13) was significantly overexpressed in CRC tissues (Fig. 1a).ISH analysis confirmed the upregulated expression pattern of IncRNA ZNFX1-AS1 in CRC tissues (Fig. 1b). Moreover, the expression of IncRNA ZNFX1-AS1 was significantly upregulated in CRC tissues with distant metastasis compared with tissues without distant metastasis (Fig. 1c). In addition, the expression of IncRNA ZNFX1-AS1 was significantly upregulated in CRC cell line (SW620, SW480, HT-29, DLD-1, RKO, LOVO) than that of human normal colon epithelial cell line CCD-112CoN (Fig. 1d).

We then examined the clinicopathological characteristics of IncRNA ZNFXA-AS1 in CRC patients, the results indicated that IncRNA ZNFX1-AS1 was significantly associated with tumor size, invasion depth, lymph node invasion, and advanced TNM stage. However, no association was found between IncRNA ZNFX1-AS1 and age, gender, and histological grade (Supplementary Table S1). We also investigated the expression of IncRNA ZNFX1-AS1 and survival in the 106 CRC patients. The Kaplan–Meier survival analysis and Log-rank test showed that IncRNA ZNFXA-AS1 was significantly correlated with overall survival and progression-free survival (Fig. 1e and f), patients with higher IncRNA ZNFX1-AS1 expression presented with worse overall and progression-free survival. In addition, univariate survival analysis indicated that tumor size, lymph node invasion, distant metastasis, TNM stage, and IncRNA ZNFX1-AS1 expression were significantly associated with overall survival and progression-free survival of CRC patients. However, multivariate cox regression analysis showed that only TNM stage and IncRNA ZNFX1-AS1 expression level were independent prognostic factors for CRC patients (Supplementary Tables S2 and S3).
lncRNA ZNFX1-AS1 promotes CRC cell proliferation and tumor growth

Specific siRNA was used to knockdown of lncRNA ZNFX1-AS1 in SW620 and LOVO cells, which presented with relatively higher expression of lncRNA ZNFX1-AS1, human lncRNA ZNFX1-AS1 transcript cDNA was constructed into pcDNA3.1 vector to ectopic expression of lncRNA ZNFX1-AS1 in SW480 and HT-29 cells, and real-time PCR was performed to confirm the knockdown and ectopic expression efficiency (Fig. 2a and Supplementary Figure S3A). CCK-8 assay showed that knockdown of lncRNA ZNFX1-AS1 significantly inhibited cell viability in SW620 and LOVO cells (Fig. 2b), whereas ectopic expression of lncRNA ZNFX1-AS1 promotes cell viability in SW480 and HT-29 cells (Supplementary Figure S3B). Colony formation assay indicated that knockdown of lncRNA ZNFX1-AS1 markedly inhibited colony formation ability in SW620 and LOVO cells (Fig. 2c), while ectopic expression of lncRNA ZNFX1-AS1 increased the colony formation ability in SW480 and HT-29 cells (Supplementary Figure S3C). To investigate the in vivo effect of lncRNA ZNFX1-AS1 on

Shi et al. Cell Death and Disease (2019) 10:150

Fig. 2 Knockdown of lncRNA ZNFX1-AS1 suppresses CRC cell proliferation and colony formation in vitro as well as tumorigenesis in vivo. 

a Relative expression of lncRNA ZNFX1-AS1 in SW620 and LOVO cells after transfection with lncRNA ZNFX1-AS1 siRNAs (*P < 0.05). b CCK-8 assay was used to detect the viability in lncRNA ZNFX1-AS1 siRNA and scramble transfected CRC cells (*P < 0.05). c Colony formation assay was performed in CRC cells transfected with lncRNA ZNFX1-AS1 siRNAs and scramble (*P < 0.05). d The stable lncRNA ZNFX1-AS1 knockdown SW620 cells were used for the in vivo tumorigenesis assays. The tumors form the two groups of nude mice were shown. e The tumor volume were measured every 5 days, and the tumor growth curve was shown (*P < 0.05). f The tumor weight of the nude mice formed by sh-ZNFX1-AS1 and sh-NC cells (*P < 0.05). g Relative expression of lncRNA ZNFX1-AS1 in nude mice tissues formed by sh-ZNFX1-AS1 and sh-NC cells (*P < 0.05)
CRC cells, we constructed two stable cell lines using a lentivirus to mediate knockdown of lncRNA ZNFX1-AS1 in SW620 cells (sh-NC and sh-ZNFX1-AS1). The cells were injected into the flanks of nude mice. The results showed that the tumor weight and tumor volume was significantly reduced in the sh-ZNFX1-AS1 group as compared with the sh-NC group (Fig. 2d and f). The real-time PCR analysis confirmed that the expression of lncRNA ZNFX1-AS1 was significantly decreased in tumors formed by sh-ZNFX1-AS1 cells (Fig. 2g).

**lncRNA ZNFX1-AS1 promotes cell migration, invasion, and metastasis of CRC cells**

A transwell assay showed that knockdown of lncRNA ZNFX1-AS1 significantly inhibited cell migration and invasion of SW20 and LOVO cells (Fig. 3a). Moreover, a wound healing assay also showed that knockdown of lncRNA ZNFX1-AS1 markedly inhibited cell migration in SW620 cells (Fig. 3b). On the contrary, ectopic expression of lncRNA ZNFX1-AS1 significantly promoted cell migration and invasion in SW480 and HT-29 cells (Fig. 3c). Moreover, knockdown of lncRNA ZNFX1-AS1 increased the level of epithelial markers such as E-cadherin, α-catenin, β-catenin while reduced the level of mesenchymal markers such as N-cadherin, vimentin, snail, and slug (Fig. 3d, e). To assess the in vivo effect of lncRNA ZNFX1-AS1 on metastasis, the cells (s-NC and sh-ZNFX1-AS1) were injected into the tail vein of nude mice. The results showed that the micro metastatic nodules in the lungs and livers were significantly fewer in nude mice injected with sh-ZNFX1-AS1 as compared with mice injected with sh-NC cells (Fig. 3f).

**lncRNA ZNFX1-AS1 functions as molecular sponge for miR-144 in gastric cancer cells**

Mounting evidences have indicated that lncRNAs can regulate the expression of targeted genes by acting as competing endogenous RNA for miRNAs or by interacting with RNA binding proteins such as PRC2. To investigate the molecular mechanism by which lncRNA ZNFX1-AS1 promotes CRC progression, we firstly determined the subcellular fraction of lncRNA ZNFX1-AS1 by real-time PCR. The result showed that lncRNA ZNFX1-AS1 is mainly located in the cytoplasm, suggesting that lncRNA ZNFX1-AS1 may regulate gene expression at the post-transcription level (Fig. 4a). Indeed, the RIP assay showed that lncRNA ZNFX1-AS1 could bind directly to Ago2, a component of the RNA-induced silencing complex (RISC) that involved in the miRNA-mediated repression of mRNA expression (Fig. 4b). This implies that lncRNA ZNFX1-AS1 might act as a ceRNA of miRNA. Using the online bioinformatic database, we found that lncRNA ZNFX1-AS1 sequence contain potential binding sites of several miRNAs, including miR-135a-5p, miR-144, miR-150, miR-15, miR-199, miR-101, and miR-10a. We then performed luciferase assay to confirm the prediction analysis. HEK293T cells were co-transfected with a luciferase plasmid containing the lncRNA ZNFX1-AS1 sequence and the miRNA mimics or negative control. The results showed that only miR-144 and miR-101 could inhibit the luciferase activity of lncRNA ZNFX1-AS1, and the inhibition effect of miR-144 is stronger (Fig. 4c). Therefore, we focused on miR-144 for further investigation, and constructed a reporter vector in which the potential miR-144 binding site in the sequence of lncRNA ZNFX1-AS1 was mutated (Fig. 4d). The results showed that the repression of luciferase activity was abolished by mutation of lncRNA ZNFX1-AS1 (Fig. 4e). Moreover, real-time PCR analysis showed that miR-144 was significantly down-regulated in CRC cell lines and tissues (Fig. 4f, g). In addition, RIP assay indicated that miR-144 and lncRNA ZNFX1-AS1 were enriched in immunoprecipitates of Ago2 as compared with control IgG (Fig. 4h). Ectopic expression of miR-144 significantly inhibited the expression of lncRNA ZNFX1-AS1 in CRC cells, whereas knockdown of lncRNA ZNFX1-AS1 had no effect on the expression of miR-144 (Fig. 4i). Real-time PCR analysis demonstrated a significantly inverse correlation between the expression of lncRNA ZNFX1-AS1 and miR-144 (Fig. 4j).

**The biological activity of lncRNA ZNFX1-AS1 is partially mediated by miR-144**

To explore the biological function of miR-144 in CRC, the SW620 and LOVO cells were transfected with miR-144 mimics or miR-144 inhibitor (Fig. 5a). The CCK-8 assay showed that the cell proliferation was significantly inhibited by ectopic expression of miR-144 while enhanced by silencing of miR-144 in SW620 and LOVO cells (Fig. 5b). Moreover, ectopic expression of miR-144 significantly inhibited the colony formation and invasion of SW620 and LOVO cells (Fig. 5c, d). To determine whether miR-144 is involved in lncRNA ZNFX1-AS1 mediated biological effects of CRC cells, SW620 cells were co-transfected with lncRNA ZNFX1-AS1 siRNA#1 and miR-144 inhibitor. To our interest, the suppression effects on cell proliferation and invasion mediated by lncRNA ZNFX1-AS1 knockdown could be partially rescued by miR-144 inhibitor (Fig. 5e–g). On the contrast, over-expression of lncRNA ZNFX1-AS1 increased the proliferation/colony formation in CRC cells, whereas overexpressing miR-144 in lncRNA ZNFX1-AS1 overexpressed cells could reverse the stimulated cell proliferation/colony formation (Supplementary Figure 4). These data implying that lncRNA ZNFX1-AS1 promotes the aggressive tumor phenotype at least in part, by regulation of miR-144 activity.
EZH2 is a direct target of miR-144 and indirectly regulated by lncRNA ZNFX1-AS1 in CRC cells

To determine the ceRNA network between lncRNA ZNFX1-AS1, miR-144 and its target genes in CRC cells, we used online bioinformatic tools (TargetScan, miRanda) to predict the potential target genes of miR-144. Moreover, we analyzed the microarray data to select out the significantly upregulated protein-coding genes in CRC. To our interest, EZH2 is one of the most obviously altered genes in the microarray analysis and also predicted by

---

**Fig. 3 Knockdown of lncRNA ZNFX1-AS1 inhibits cell migration, invasion, in vitro as well as metastasis in vivo.**

a) The migration and invasion abilities were detected by transwell assay in SW620 and LOVO cells after transfection of lncRNA ZNFX1-AS1 siRNAs (*P* < 0.05).

b) The migration was measured by wound healing assay in SW620 cells after transfection of lncRNA ZNFX1-AS1 siRNAs (*P* < 0.05).

c) The cell invasion abilities were measured in SW480 and HT-29 cells after ectopic expression of lncRNA ZNFX1-AS1 (*P* < 0.05).

d) Immunofluorescence analysis showed that knockdown of lncRNA ZNFX1-AS1 increased the level of epithelial marker E-cadherin while reduced the level of mesenchymal marker N-cadherin.

e) Real-time PCR showed that knockdown of lncRNA ZNFX1-AS1 increased the level of epithelial markers such as E-cadherin, α-catenin, β-catenin while reduced the level of mesenchymal markers such as N-cadherin, vimentin, snail and slug.

f) The stable lncRNA ZNFX1-AS1 knockdown SW620 cells were used for the in vivo metastasis assay, the micro-metastasis in the lung and in the liver from the two groups were shown (*P* < 0.05).
Fig. 5 The effects of miR-144 on CRC cells. a Relative expression of miR-144 was determined by real-time PCR in SW620 and LOVO cells after transfection with miR-144 mimics, miR-144 inhibitor or control miRNA. b CCK-8 assay showed that the cell proliferation was inhibited by miR-144 mimics and stimulated by miR-144 inhibitor in SW620 and LOVO cells (*P < 0.05). c The colony formation abilities were suppressed in SW620 and LOVO cells by miR-144 (*P < 0.05). d The cell invasion capacities were inhibited in SW620 and LOVO cells by miR-144 (*P < 0.05). e The HEK293T cells were co-transfected with the wild type (wt) or mutant type (mt) lncRNA ZNFX1-AS1 plasmid and miR-144 or empty plasmid vector, and the luciferase activities were measured (*P < 0.05). f The relative expression of miR-144 in CRC cell lines (SW620, SW480, HT-29, DLD-1, RKO, LOVO) and immortalized colon epithelial cell line CCD-112CoN (*P < 0.05). g The relative expression of miR-144 in CRC tissues and adjacent normal tissues; in CRC issues with and without distant metastasis (*P < 0.05). h RIP assays were performed in SW620 and LOVO cells, relative RNA level in immunoprecipitates were presented as fold change in Ago2 relative to IgG immunoprecipitates (*P < 0.05). i The relative expression of lncRNA ZNFX1-AS1 in SW620 and LOVO cells transfected with miR-144 or negative control vector, the relative expression of miR-144 in SW620 and LOVO cells after transfection with lncRNA ZNFX1-AS1 siRNA or scramble (*P < 0.05). j Association analysis of the expression between lncRNA ZNFX1-AS1 and miR-144 in 106 CRC tissues (r = −0.76, P < 0.001).
bioinformatic tools (Fig. 6a, Supplementary Figure S1B), therefore, we focus on EZH2 in the further study. Ectopic expression of miR-144 significantly decreased the mRNA and protein level of EZH2 in SW620 and LOVO cells (Fig. 6b, c), as IncRNA ZNFX1-AS1 could sponge to miR-144, we wondered whether IncRNA ZNFX1-AS1 can regulate the expression of EZH2, to our interest, knockdown of IncRNA ZNFX1-AS1 could significantly reduce the mRNA and protein level of EZH2 in SW620 and LOVO cells (Fig. 6b, c). Next, we explored whether the luciferase activity of EZH2 3′-UTR could be reduced by miR-144, the EZH2-wt-3′-UTR, EZH2-mt-3′-UTR, miR-144 mimic or non-target control miRNA were co-transfected into the HEK293T cells, the luciferase of EZH2-wt-3′-UTR was significantly reduced by miR-144 compared with non-target control miRNA, but this suppression effect was not observed in the EZH2-mt-3′-UTR (Fig. 6d). In addition, we found a significantly positive association between the expression of IncRNA ZNFX1-AS1 and EZH2 in 106 CRC tissues (Fig. 6e). As expected, an inverse association as found between the expression of miR-144 and EZH2 (Supplementary Figure 5). These results suggest that IncRNA ZNFX1-AS1 regulates EZH2 expression through post-transcriptional modulation of miR-144.

**EZH2 is upregulated in CRC and promotes CRC cell proliferation and invasion**

To investigate the oncogenic role of EZH2 in CRC cells, we measured the expression of EZH2 in CRC tissues and cell lines. IHC showed that EZH2 protein was significantly overexpressed in CRC tissues as compared with adjacent normal tissues (Fig. 7a), and Real-time PCR analysis indicated that EZH2 mRNA was significantly upregulated in CRC tissues/cells compared with normal tissues/cells (Fig. 7b, c). Real-time PCR analysis confirmed the knockdown efficiency of EZH2 in SW620 and LOVO cells (Fig. 7d). Knockdown of EZH2 significantly inhibited cell proliferation of SW620 and LOVO cells (Fig. 7e). Likewise, knockdown of EZH2 markedly inhibited the colony

---

**Fig. 6 EZH2 is a direct target of miR-144 and is indirectly regulated by IncRNA ZNFX1-AS1 in CRC cells.**

- **a** Schematic view of putative miR-144 binding sites in the wild type (wt) and mutant type (mt) of EZH2 3′-UTR.
- **b, c** The relative expression of EZH2 mRNA and protein in SW620 and LOVO cells after transfection with miR-144 mimics or IncRNA ZNFX1-AS1 siRNAs (*P < 0.05).
- **d** The HEK293T cells were co-transfected with wild type or mutant type EZH2 3′-UTR, miR-144 expression plasmid or control vector, and the luciferase activities were measured (*P < 0.05).
- **e** Association analysis of the relationship between IncRNA ZNFX1-AS1 and EZH2 expression in 106 CRC tissues (r = 0.71, P < 0.001)

---

Official journal of the Cell Death Differentiation Association
Fig. 7 The effects of EZH2 on CRC cells.  

(a) The expression of EZH2 in CRC tissues and adjacent normal tissues by IHC.  

(b) Relative expression of EZH2 mRNA in CRC cell lines (SW620, SW480, HT-29, DLD-1, RKO, LOVO) and immortalized colon epithelial cell line CCD-112CoN (*P < 0.05).  

(c) Relative expression of EZH2 mRNA in CRC tissues and adjacent normal tissues (*P < 0.05).  

(d) The mRNA level of EZH2 in SW620 and LOVO cells as measured by Real-time PCR after knockdown of EZH2.  

(e) The cell viabilities of SW620 and LOVO cells were measured by CCK-8 assays after transfected with si-EZH2 or control siRNA (*P < 0.05).  

(f) The colony formation capacities of SW620 and LOVO cells after transfected with si-EZH2 or control siRNA (*P < 0.05).  

(g) The invasion abilities of SW620 and LOVO cells after transfected with si-EZH2 or control siRNA (*P < 0.05).  

(h) The cell viabilities of SW620 and LOVO cells were measured by CCK-8 assays after transfected with si-EZH2, miR-144 inhibitor or both (*P < 0.05).  

(i) The invasion abilities of SW620 and LOVO cells after transfected with si-EZH2 or control siRNA (*P < 0.05).
formation and cell invasion ability in SW620 and LOVO cells (Fig. 7f, g). Moreover, the promoted cell proliferation and invasion by miR-144 inhibition could be reversed by EZH2 knockdown in SW620 and LOVO cells (Fig. 7h, i).

Discussion

Increasing evidence revealed that IncRNAs play critical role in the development and metastasis of tumors. In this study, we identified a set of IncRNAs that involved in the progression of CRC, among this IncRNAs, IncRNA ZNFX1-AS1 was confirmed as one of the most differentially expressed IncRNA between CRC tissues and normal tissues. High expression of IncRNA ZNFX1-AS1 was significantly associated with aggressive tumor phenotypes (larger tumor size, invasion depth, lymph node invasion, and TNM stage) of CRC patients. Moreover, increased expression of IncRNA ZNFX1-AS1 was associated with poor overall and progression-free survival in CRC patients. In vitro and in vivo experiments demonstrated that IncRNA ZNFX1-AS1 could promote the proliferation, invasion, as well as tumorigenesis and metastasis of CRC cells. These results suggest that IncRNA ZNFX1-AS1 plays a key oncogenic role in the progression of CRC and could be considered to be a potential predictor of prognosis for CRC patients. Previously, Wang et al reported that IncRNA ZNFX1-AS1 acted as a tumor suppressor and inhibited the growth of hepatocellular carcinoma cells, this implies that IncRNA ZNFX1-AS1 expression pattern may be tissue and cell-specific, and IncRNA ZNFX1-AS1 can be oncogenic or tumor-suppressive depending on the tumor type and cellular microenvironment.

Recent studies indicated that IncRNAs are frequently involved in the ceRNA network, where IncRNAs could regulate the miRNA target gene expression by binding miRNA and titrating off their binding with protein-coding messengers. For instance, Linc01234 promotes gastric cancer progression by functioning as a ceRNA of miR-204-5p. IncRNA UICLM mediated CRC liver metastasis by sponging to miR-215 to regulate the expression of ZEB1; IncRNA HOXA11-AS promotes the cell proliferation through interacting with miR-1297 in gastric cancer. In this study, we found that IncRNA ZNFX1-AS1 was mainly located in the cytoplasm and could be enriched by Ago2 in CRC cells, which implicates that IncRNA ZNFX1-AS1 might be involved in the ceRNA network. The online bioinformatics indicated and luciferase activity assay indicated miR-144 was sponged by IncRNA ZNFX1-AS1. miR-144 has been found to be downregulated in various tumors and generally functions as a tumor suppressor. Zhang and colleagues showed that miR-144 inhibits cancer metastasis by targeting ADAMTS5 and ADAM10. In another study, Ren et al indicated that miR-144 was down-regulated in Osteosarcoma, and ectopic expression of miR-144 inhibited cell proliferation, and metastasis in vitro and in vivo. In our study, we found that miR-144 was significantly down-regulated in CRC, ectopic expression of miR-144 inhibited CRC cell proliferation, migration, and metastasis both in vitro and in vivo. In accordance with our study, Iwaya et al found that down-regulation of miR-144 is associated with CRC progression via activation of the mTOR signaling pathway. Our results uncover the interaction between IncRNA ZNFX1-AS1 and miR-144 in mediating the progression of CRC.

In general, IncRNAs exert their function by acting as ceRNAs through de-repression of the miRNA target genes. We found that EZH2 was the potential target of miR-144 involved in the ceRNA network. The expression of EZH2 was significantly upregulated in CRC tissues; ectopic expression of miR-144 decreased the expression of EZH2 in CRC cells. Moreover, luciferase activity assay confirmed that miR-144 regulated EZH2 expression by directly binding to its 3′-UTR. This is the first study to find the regulation relationship between miR-144 and EZH2 in CRC. Consistent with our results, previous reports indicated that miR-144 target EZH2 in bladder cancer. EZH2 has been found to be frequently dysregulated and is involved in the regulation of tumor progression in multiple tumors. In accordance with previous studies, we found that EZH2 was significantly upregulated in CRC tissues and cell lines. Knockdown of EZH2 inhibited cell proliferation, invasion and metastasis of CRC cells. Moreover, the cell proliferation and invasion ability stimulated by miR-144 inhibition could be reversed by knockdown of miR-144, suggesting that EZH2 is essential for the miR-144 mediating biological effects in CRC cells. More and More studies indicated that mutations or aberrant upregulation of EZH2 occur frequently in human cancers. However, clinical benefits of EZH2 inhibitor remain unsatisfactory, this might because that EZH2 is involved in many different signaling pathways and regulated by many different molecules in different tumor types. Here, we showed the evidence for the axis ZNFX1-AS1-miR144-EZH2. What’s more, ZNFX1-AS1 promotes cell proliferation and invasion in CRC cells. Increasing evidences showed that silencing of lncRNAs via siRNAs could be a useful therapeutic strategy but is complicated because of IncRNAs extensive secondary structure or intracellular localization. Gutschner developed a highly effective silencing method using genomic integration of RNA destabilizing elements, which may be useful to silence IncRNA expression in cancer patients. A combination of inhibition of ZNFX1-AS1 and EZH2 might be more effective in treating CRC patients. However, further studies including pre-clinical trials are needed to explore these issues.
Conclusions
In conclusion, we identified a novel lncRNA ZNFX1-AS1 which promotes CRC cell proliferation, invasion, tumorigenesis, and metastasis by acting as a ceRNA of miR-144 to regulate the expression of EZH2. The present study shed more light on the understanding of the lncRNA-miRNA-mRNA ceRNA network of CRC, and lncRNA ZNFX1-AS1 might be used as a potential diagnostic and therapeutic target for CRC.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its additional files.

Authors’ contributions
P.G. conceived and designed the project. S.L.L., H.X.H. carried out most of the experiments. B.L. performed the statistical analysis. H.X.X. collected the clinical and pathological data. X.Y. and D.Q. involved in the design of the study. Y.S.L. gave support in doing experiments and reviewed the manuscript. S.L.L. wrote the manuscript, and all authors read and approved the final manuscript.

Conflict of interest
The authors declare that they have no conflict of interest.

Ethics approval and consent to participate
The human tissue study protocol was approved by the ethics committee of the Union hospital, Tongji medical college, Huazhong university of science and technology. All the animal experiments were performed according to the National Institutes of Health animal use guidelines on the use of experimental animals.

Funding
National Natural Sciences Foundation of China (No.81602607; No. 81200313); Applied Basic Research of Science and Technology Projects of Wuhan (No. 2014060101010046).

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41419-019-1332-8).

Received: 6 October 2018 Revised: 5 December 2018 Accepted: 2 January 2019
Published online: 15 February 2019

References
1. Amaral, P. P., Dinger, M. E., Mercer, T. R. & Mattick, J. S. The eukaryotic genome as an RNA machine. Science 319, 1787–1789 (2008).
2. Gutman, M. et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223–227 (2009).
3. Jia, Y. J. et al. HDAC6 regulates microRNA-27β that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma. Leukemia 32, 703–711 (2018).
4. Capizzi, M., Strapazzon, F., Cianfanelli, V., Papaleo, E. & Cecconi, F. MIR7-3HG, a MYC-dependent modulator of cell proliferation, inhibits autophagy by a regulatory loop involving AMBRA1. Autophagy 13, 554–566 (2017).
5. Valen, N. et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 25, 469–483 (2014).
6. Nagano, T. & Fraser, P. No-nonsense functions for long noncoding RNAs. Cell 145, 178–181 (2011).
7. Wang, K. C. & Chang, H. Y. Molecular mechanisms of long noncoding RNAs. Mol. Cell 43, 904–914 (2011).
8. Liu, Y. et al. Tissue-specific RNA-Seq in human evoked inflammation identifies blood and adipose lncRNA signatures of cardiometabolic diseases. Arterioscler. Thromb. Vasc. Biol. 34, 902–912 (2014).
9. Wang, K. C. et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472, 120–124 (2011).
10. Tsa, M. C. et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689–693 (2010).
11. Rinn, J. L. & Chang, H. Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 81, 145–166 (2012).
12. Liu, Y. W. et al. LIN28/STAR epigenetically silences miR-14a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis. 6, e1802 (2015).
13. Chang, S., Chen, B., Wang, X., Wu, K. & Sun, Y. Long non-coding RNA XIST regulates PTEN expression by sponging miR-181a and promotes hepatocellular carcinoma progression. BMC Cancer 17, 248 (2017).
14. Lu, W. et al. Long non-coding RNA Inc00673 regulated non-small cell lung cancers proliferation, migration and invasion by sponging miR-150. Sci. Rep. 6, 36625 (2016).
15. Zheng, J. et al. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nat. Genet. 48, 747–757 (2016).
16. Sha, M. et al. Long non-coding RNA MIAT promotes gastric cancer growth and metastasis through regulation of miR-141/DDX5 pathway. J. Exp. Clin. Cancer Res. 37, 58 (2018).
17. Lu, Z. et al. Long non-coding RNA NXIL inhibits migration and invasion of non-small cell lung cancer via NF-kappaB/Sna1 pathway. J. Exp. Clin. Cancer Res. 36, 54 (2017).
18. Tome, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).
19. Goldstein, D. A., Zeichner, S. B., Barrick, C. M., Neustadtter, E. & Flowers, C. R. Metastatic colorectal cancer: a systematic review of the value of current therapies. Clin. Colorectal Cancer 15, 1–6 (2016).
20. Chaffier, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559–1564 (2011).
21. Manfredi, S. et al. Epidemiology and management of liver metastases from colorectal cancer. Ann. Surg. Oncol. 24, 254–259 (2009).
22. Chen, D. L. et al. Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. Theranostics 7, 4836–4849 (2017).
23. Chen, D. L. et al. Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecule sponge of miR-101 to modulate E2F2 expression. J. Exp. Clin. Cancer Res. 35, 142 (2016).
24. Lu, Y. X. et al. Inhibition of the NF-kappaB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Lett. 380, 87–97 (2016).
25. Chen, D. L. et al. L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. J. Hematol. Oncol. 7, 50 (2014).
26. Kotake, Y. et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of (p15)(Ink4b) tumor suppressor gene. Oncogene 30, 1956–1962 (2011).
27. Wang, T. et al. Long non-coding RNA ZNFX1-AS1 suppresses growth of hepatocellular carcinoma cells by regulating the methylation of miR9. Oncotarget 9, 5005–5016 (2016).
28. Jalal, S., Bhartiya, D., Lalwani, M. K., Sivasubbu, S. & Scaria, V. Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS. One. 8, e53823 (2013).
29. Salmens, L., Poliseno, L., Tay, Y., Kats, L. & Pandolfi, P. P. A cell RNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146, 353–358 (2011).
30. Chen, X. et al. Long Noncoding RNA LINCO1234 Functions as a Competing Endogenous RNA to Regulate CBB Expression by Sponging mir-204-5p in Gastric Cancer. Clin. Cancer Res. 24, 2002–2014 (2018).
31. Sun, M. et al. LncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1. Cancer Res. 76, 6299–6310 (2016).
32. Sun, L. et al. MiR-144 promotes beta-amyloid accumulation-induced cognitive impairments by targeting ADAM10 following traumatic brain injury. Onco-target 8, 59181–59203 (2017).
33. Ren, Y. F., Zhang, T. H., Zhong, S., Zhao, Y. T. & Lv, Y. N. miR-144 suppresses proliferation and induces apoptosis of osteosarcoma cells via direct regulation of mTOR expression. Oncol. Lett. 15, 1163–1169 (2018).

34. Iwaya, T. et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis 33, 2391–2397 (2012).

35. Guo, Y. et al. miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. Febs. J. 280, 4531–4538 (2013).

36. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).

37. Raman, J. D. et al. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 11, 8570–8576 (2005).

38. Huang, X. et al. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell 175, 186–199 e119 (2018).

39. Gutschner, T., Baas, M. & Diederichs, S. Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases. Genome Res. 21, 1944–1954 (2011).